Minimally Invasive Ridge Splitting Versus the Conventional Open Flap Technique
Quantitative Assessment of Bone Comparing the Minimally Invasive Ridge Splitting Versus the Conventional Open Flap Technique
1 other identifier
interventional
16
2 countries
2
Brief Summary
The goal of this clinical trial is to compare implant stability, and crestal bone loss, when using minimal invasive ridge splitting versus convenient open flap technique. The main question is Does Minimal Invasive Implant ridge splitting ("transmucosal" without flap) influence the implant stability and crystal bone loss, when compared with the conventional open flap techniques? Researchers will compare Group A: Minimal Invasive Implant ridge splitting and Group B: Triangular flap technique is used to see if there is significant difference between the two groups when measuring implant stability, and crestal bone density.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jul 2023
Typical duration for not_applicable
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 31, 2023
CompletedFirst Submitted
Initial submission to the registry
March 15, 2024
CompletedFirst Posted
Study publicly available on registry
March 25, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2025
CompletedMarch 26, 2024
March 1, 2024
1.9 years
March 15, 2024
March 24, 2024
Conditions
Outcome Measures
Primary Outcomes (2)
Implant stability.
Implant Stability Quotient (ISQ) evaluation via Ostell device for implant stability measurement, it measures on a scale from 1 to 100 and is a measure of the stability of an implant, less than 60 indicates low stability, 60-69 indicates medium stability, 70 and more indicates high stability. Method of aggregation: Mean and standard deviation. .
immediate postoperative, 1, 2, and 3 months post operative.
CBCT assessment
Bone density at the implant site in House field unit. A Hounsfield unit reading of 1250 and above indicates D1 bone. A Hounsfield reading between 850 to 1250 units is indicative of D2 bone. A Hounsfield reading between 350 and 850 units is indicative of type D3 bone. A Hounsfield reading between 150 and 350 units is indicative of D4 bone. Method of aggregation: Mean and standard deviation.
measurement points: preoperative, immediately postoperative, and 12 months postoperative, unless indicated otherwise e.g., Complications).
Secondary Outcomes (2)
Postoperative Pain
to be completed by day 7 postoperative, describing the pain felt.
Operation Time
Time of the procedure from the beginning to the end.
Study Arms (2)
Minimal Invasive Implant ridge splitting
ACTIVE COMPARATORUsing minimally invasive implant placement in atrophied ridge without mucoperiosteal flap, and specially designed implant shaped expanders.
conventional open flap ridge splitting implantation.
ACTIVE COMPARATORUsing the conventional open flap technique with mucoperiosteal elevation to expose the ridge with the use of conventional bone expanders and chisels.
Interventions
Specially designed ridge splitting instrumentation by Champions Implant GmbH which is implant shaped expanders.
Mucoperiosteal elevation and ridge splitting using conventional ridge expanders.
Eligibility Criteria
You may qualify if:
- Patients with atrophic posterior mandibular ridge with edentulous area 30-40 mm, minimum width 3-4 mm, and adequate height indicated for implant placement \>9 mm.
- Patient with Bone density D2 and D3.
- Good general systemic condition.
- Committed patient to attend follow up appointment.
You may not qualify if:
- Patients with systemic diseases that may affect the healing process of hard or soft tissues (e.g., uncontrolled diabetes mellitus).
- Patient on medication that could hinder the normal healing process (e.g., steroids, immunosuppressant)
- Patients with intra-bony lesions or infections.
- Patient with bad habits (e.g. alcohol or Substance abuse).
- Patient who received head and neck radiotherapy or chemotherapy in the last 10 years.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Faculty of Dentistry Cairo University
Cairo, 35855, Egypt
Future Dental Academy GmbH
Flonheim, Rhineland-Palatinate, D-55237, Germany
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Emad Deif, Prof.
Head of Oral and Maxillofacial Surgery Department - Faculty of Dentistry Cairo University
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Oral and Maxillofacial Surgeon
Study Record Dates
First Submitted
March 15, 2024
First Posted
March 25, 2024
Study Start
July 31, 2023
Primary Completion
July 1, 2025
Study Completion
July 1, 2025
Last Updated
March 26, 2024
Record last verified: 2024-03
Data Sharing
- IPD Sharing
- Will not share